Mounjaro vs Zepbound
These brands contain tirzepatide. Compare their approved uses, formulations, and self-pay prices. Products are not interchangeable.
| Compare | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | TirzepatideGIP/GLP-1 | TirzepatideGIP/GLP-1 |
| How it is taken | Injection Once weekly | Injection Once weekly |
| Manufacturer | Eli Lilly | Eli Lilly |
What was actually compared
No direct trial comparing these exact brands is included in our reviewed catalog. Sharing an ingredient does not establish the same outcomes at different doses or formulations.
Weight-loss results by formulation
Each result belongs to its named trial and dose. Separate trials have different participants and methods; these figures are not a direct comparison.
| Compare | Mounjaro | Zepbound |
|---|---|---|
| Injection evidence | No reviewed weight-loss result for this brand and formulation. | −20.9% (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound)) SURMOUNT-1 · -20.9% at 72 wks 15 mg weekly (Zepbound) Accounts for treatment discontinuation |
Entry price and maintenance price
Self-pay quotes, not insurance estimates. Each figure identifies the product, provider, and dose where published.
| Compare | Mounjaro | Zepbound |
|---|---|---|
| Injection prices | Advertised entry price from $499/28 days≈ $534.64 per 30 days at this quoted rate Checked Mounjaro single-dose pens LillyDirect (Eli Lilly) · Manufacturer direct self-pay, four weekly pens; published starting rate at each dose Price conditionsself-pay, four weekly pens; published starting rate at each dose The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. Four once-weekly pens cover 28 days. 28-day supply Published maintenance dose from $499/28 days≈ $534.64 per 30 days at this quoted rate Checked At 15 mg Mounjaro single-dose pens LillyDirect (Eli Lilly) · Manufacturer direct Published price at 15 mg Price conditionsPublished price at 15 mg The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. Four once-weekly pens cover 28 days. The same starting rate is published for all six strengths, 2.5-15 mg. Taxes and additional fees may apply. 28-day supply | Advertised entry price $299-$449/28 days≈ $320.36 per 30 days at this quoted rate Checked Zepbound KwikPen (multi-dose pen) LillyDirect (Eli Lilly) · Manufacturer direct self-pay cash, by dose ($299 / $399 / $449) Price conditionsself-pay cash, by dose ($299 / $399 / $449) Four weekly doses per pen; pen needles must be purchased separately. $299 at 2.5 mg, $399 at 5 mg, and $449 at higher doses under the Self Pay Journey offer with a refill within 45 days. 28-day supply Published maintenance dose $449/28 days≈ $481.07 per 30 days at this quoted rate Checked At 15 mg Zepbound KwikPen (multi-dose pen) LillyDirect (Eli Lilly) · Manufacturer direct Published price at 15 mg Price conditionsPublished price at 15 mg Four weekly doses per pen; pen needles must be purchased separately. $299 at 2.5 mg, $399 at 5 mg, and $449 at higher doses under the Self Pay Journey offer with a refill within 45 days. Self Pay Journey price for 7.5-15 mg with a refill within 45 days; otherwise $499 (7.5 mg) or $699 (10-15 mg). Pen needles cost extra. 28-day supply |
How these quotes are selected
For each price basis, we prefer a recently checked manufacturer-direct quote, then a recently checked provider quote for that brand and formulation. Within each group, documented 30-day costs come first, lowest to highest. Quotes without a documented supply period have no cost rank. Older quotes appear as dated references only when no current quote is tracked. Providers may differ between entry and maintenance prices. Missing maintenance prices are never replaced with entry prices. Compounded products, combined brand quotes, and membership-only fees are excluded. Prices at different doses are not equivalent treatment costs; confirm supply length, eligibility, and added fees.
Every cash quote was checked on or after . Each quote shows its own check date. A quoted maintenance dose is not a dosing recommendation. Our methodology
Approved uses by formulation
Eligibility, contraindications, and warnings are in each product's full prescribing information.
| Compare | Mounjaro | Zepbound |
|---|---|---|
| Injection | Glucose control in adults and children 10+ with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high cardiovascular risk. US prescribing information (Mounjaro Injection prescribing information)Reviewed Sep 6, 2026 | Weight management in adults with obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity. US prescribing information (Zepbound Injection prescribing information)Reviewed Sep 6, 2026 |